LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

LLY

1,145.52

-0.3%↓

JNJ

239.29

+1.3%↑

ABBV

225.65

-0.38%↓

UNH

407.9

-0.49%↓

MRK

117.62

-1.96%↓

Home・Stock List・Incyte Corp

Incyte Corp

Open

SectorHealthcare

106.16 3.31

Buy Sell

Overview

Share price change

24h

Current

Min

102.36

Max

110.19

Key metrics
By Trading Economics
Income	4.1M 303M
Sales	-234M 1.3B
P/E Sector Avg	14.215 49.888
EPS	1.81
Profit margin	23.834
Employees	2,844
EBITDA	-47M 368M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+6.93% upside

Dividends
By Dow Jones
Next Earnings	28 Jul 2026

Market Stats
By TradingEconomics
Market Cap	1.1B 20B
Previous open	102.85
Previous close	106.16

News Sentiment

By Acuity

32%

68%

81 / 344 Healthcare

Incyte Corp Chart

Past performance is not a reliable indicator of future results.

Related News

9 Jun 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 Jun 2026, 23:45 UTC

Acquisitions, Mergers, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 Jun 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 Jun 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 Jun 2026, 23:43 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 Jun 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 Jun 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 Jun 2026, 20:51 UTC

Earnings

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jun 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Jun 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 Jun 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 Jun 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 Jun 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 Jun 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 Jun 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 Jun 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 Jun 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 Jun 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 Jun 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 Jun 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 Jun 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 Jun 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 Jun 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer Comparison

Price change

Incyte Corp Forecast

Price Target

By TipRanks

6.93% upside

12 Months Forecast

Average 110.38 USD 6.93%

High 140 USD

Low 75 USD

Based on 19 Wall Street analysts offering 12 month price targets forIncyte Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Incyte Corp - Dist in the past 3 months.

Sentiment

By Acuity

81 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation